Cancer research results excite scientists and investors

Article Abstract:

Eloxatin, a chemotherapy drug manufactured by Sanofi-Synthelabo SA, is effective as a first line treatment to shrink tumors, as a last-resort treatment when other chemotherapy drugs have failed and as preventive medicine administered after surgery. The approval of the drug by the Food and Drug Administration (FDA) has excited the physicians and scientists in Malvern who managed clinical development of the drug.

Government regulation (cont), Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Science & research, Pharmaceutical Preparation Manufacturing, Drugs, Pharmaceutical Preparations, Metabolic Agents NEC, Metabolic Agents, Research, Laws, regulations and rules, Government regulation, Powers and duties, Cancer, Chemotherapy, United States. Food and Drug Administration

---

Medco settles with U.S., 20 states

Article Abstract:

Medco Health Solutions Inc., the nation's largest pharmacy-benefits manager, has agreed to pay $29.3 million to settle allegations by the attorney general in 20 states in 2004. Medco, which manages the prescription-drug benefits for 62 million Americans, reported that it reached a separate virtually identical agreement with the Justice Department on business practices.

United States, Drugs Reimbursement Benefits, Company legal issue, Cases, Discipline, Prescription drug plans, MHS, Medco Health Solutions Inc.

---

Adolor seeks approval of first drug

Article Abstract:

Adolor Corp., a small Exton pharmaceutical company in pursuit of its first product sought U.S. approval of a drug to speed gastrointestinal recovery after surgery. As the medicine, called Entereg addresses a medical condition for which there is no approved treatment, and Adolor has asked the Food and Drug Administration to give the new drug application priority review.

Product development, Drug therapy, Licensing, certification and accreditation, Gastrointestinal diseases, Adolor Corp., Entereg (Medication)

Similar abstracts:

• Abstracts: Commerce is branching out. PSDS investors still on hold with U.S. suit. American Business reports $5 million loss
• Abstracts: Wyeth beats quarterly forecast despite 41% drop. Drug could ease patients' discomfort - and investors'
• Abstracts: Phila. White Pages could turn yellow with age. Year 2000 bug takes a bite of SCT. RCN's 4th-qtr. Losses bigger than expected
• Abstracts: HomeLife Furniture Corp. will not resume operations. Steel firm files for Chapter 11 shelter. Excite@Home users may lose Internet link
• Abstracts: A flag of convenience and quality on the seas. InterDigital soars after U.N. report. Chamber's new task: Bringing home jobs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.